Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: J Thorac Oncol. 2021 May 25;16(10):1694–1704. doi: 10.1016/j.jtho.2021.05.004

Figure 5: Five year overall.

Figure 5:

Stratified by A) Cancer cell-specific MHCII status, and levels of TME immune infiltration based on the cohort median of total B) CD4+, C) CD8+, D) CD14+, or E) CD19+ cells.